Compare · RVTY vs TLIS
RVTY vs TLIS
Side-by-side comparison of Revvity Inc. (RVTY) and Talis Biomedical Corporation (TLIS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TLIS operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $13.82B, about 95.2x TLIS ($145.1M).
- RVTY has hit the wire 6 times in the past 4 weeks while TLIS has been quiet.
- RVTY has more recent analyst coverage (22 ratings vs 5 for TLIS).
- Company
- Revvity Inc.
- Talis Biomedical Corporation
- Price
- $121.86-1.65%
- $4.41+6.78%
- Market cap
- $13.82B
- $145.1M
- 1M return
- +5.35%
- -
- 1Y return
- +47.67%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 22
- 5
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest RVTY
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
- RBC Capital Mkts initiated coverage on Revvity with a new price target
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits